Introduction {#sec1}
============

Esophageal atresia (EA) with or without tracheoesophageal fistula is a developmental defect of the upper gastrointestinal tract, representing the most common congenital anomaly of the esophagus. The overall incidence ranges from one in every 2400 to 4500 live births worldwide.[@bib1] Since the first successful surgical repair in 1941, a significant improvement in survival has been reached. Advances in neonatal intensive care, neonatal anesthesia, and surgical techniques have profoundly changed the natural history of EA, limiting mortality to cases with coexistent severe life-threatening anomalies, such as congenital heart disease.[@bib2] Therefore, long-term morbidity and quality-of-life issues have now become priority targets in managing EA patients.[@bib3] Anastomotic stricture (AS) formation, esophageal dysmotility-related conditions, such as gastroesophageal reflux disease (GERD) and dysphagia, as well as respiratory problems, are the most common complications encountered in EA survivors.[@bib3] Furthermore, emerging data suggest that EA patients are more likely to develop eosinophilic esophagitis (EoE) compared to general population.[@bib3]^,^[@bib4]

EoE is currently defined as a chronic, immune-mediated or antigen-mediated esophageal disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation that is limited to the esophagus.[@bib5] Recognition of the disease has been increasing over the last 15 years. Current estimated annual incidence is approximately 10/100,000 cases, while prevalence ranges from 10 to 57 cases per 100,000 persons.[@bib6]

Recently, the joint European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidelines on long-term management of EA suggest excluding EoE in all symptomatic EA patients, especially before proceeding to anti-reflux surgery.[@bib3]

Despite recent attention to the coexistence of EoE in patients with EA, current literature remains limited, as less than 100 cases have been detailed in the literature, with few of those cases from Europe and none from Italy.

The purpose of the present retrospective study was to further examine the relationship between EA and EoE. The primary aim was to establish the prevalence of EoE among surviving patients with EA from Italy and describe their demographic and disease characteristics. The secondary aim was to compare features of EoE in patients with EA (EA/EoE group) with those of patients from general population (EoE group).

Methods {#sec2}
=======

We conducted a retrospective chart review of children with EA and EoE, from January 2005 to October 2018. Baseline demographics, disease history, and outcome data were analyzed. The authors sent notification of the study to the Ethic Committee (according to the National Guidelines for Observational Study of the Italian Drug Agency, "Agenzia Italiana del Farmaco - AIFA", retrospective studies do not need formal approval by the Ethic Committee and can be initiated by the proposer after notification, using the procedure of silence/consent). Personal data of patients have been collected totally unidentifiably, and patients' confidentiality was protected.

EA patients {#sec2.1}
-----------

EA patients had surgery at our institution or in other centers. The type of EA was classified according to the Gross classification (A-E classification).[@bib7] The presence of associated anomalies, such as cardiac anomaly or VACTERL (Vertebra, Anorectal, Cardiac, Tracheo-Esophageal, Renal, Limb) association was noted. Long-gap EA (LGEA) was defined as an anatomic distance of ≥3 vertebral bodies between the proximal and distal esophageal segments and was determined according to the hospital protocol.[@bib8] AS was defined as a luminal narrowing at the level of the esophageal anastomosis leading to a functional esophageal impairment and related symptoms.[@bib3] Recurrent and refractory AS were defined according to the ESPGHAN and European Society of Gastrointestinal Endoscopy (ESGE) guidelines on pediatric endoscopy.[@bib9] As per ESPGHAN-NASPHAN guidelines, EA children with symptoms of esophageal dysfunction, such as dysphagia and feeding difficulties, regurgitation and vomiting, food impaction, cough or drooling, first underwent testing to rule out AS. In case of no evidence of AS, other diagnoses were considered including esophageal dysmotility, gastroesophageal reflux disease (GERD), recurrent tracheoesophageal fistula, tracheomalacia, laryngeal clefts, and EoE.[@bib10] In patients with AS who underwent endoscopic esophageal dilation, biopsy specimens were not routinely collected, unless endoscopic features suggestive of EoE were present (as detailed below). Conversely, routine esophageal biopsy sampling was carried out to rule out EoE in symptomatic patients without AS. EoE diagnosis and treatment were based on current ESPGHAN guidelines (as detailed below).[@bib4]

EoE patients {#sec2.2}
------------

EoE patients received diagnosis at our institution or elsewhere. All EoE patients were followed-up in the dedicated multidisciplinary eosinophilic gastrointestinal disease clinic, provided with a comprehensive evaluation from a highly experienced team of pediatric gastroenterologists, allergists, and dietitians. According to ESPGHAN guidelines on EoE, diagnosis was made with both clinical and histological features. Symptoms included dysphagia, vomiting, feeding difficulties, abdominal/chest pain, other symptoms suggestive of GERD and food impaction. Multiple biopsies were obtained from distal, mid, and proximal esophagus. At least 15 eosinophils in at least 1 high-power microscopy field (EOS/HPF) were needed for EoE diagnosis. Endoscopic typical features were noted, such as multiple esophageal rings, linear furrows, white plaques, and crêpe-paper mucosa. As per current recommendations, all patients received a trial of 8 weeks of proton pump inhibitors (PPIs) (esomeprazole or lansoprazole 2 mg/kg/day) followed by endoscopic and histological reassessment.[@bib4] Patients showing clinico-histological response to PPIs were labeled as having PPI-responsive esophageal eosinophilia (PPI-REE). PPI-nonresponsive children underwent dietary treatment (amino acid-based formula or empiric elimination diet) and/or swallowed topical corticosteroids (fluticasone propionate or oral viscous budesonide).[@bib4] Data on personal and family history of allergic disorders were collected, including bronchospasm, allergic rhinitis, eczema, and food allergy. All patients underwent skin prick testing and specific IgE evaluation for both food and inhalant allergens.

Upper gastrointestinal endoscopy {#sec2.3}
--------------------------------

In all patients, any acid suppression medication was discontinued at least 4 weeks before upper gastrointestinal endoscopy (UGIE). UGIEs were performed under general anesthesia with a pediatric video endoscope (Olympus GIF N180, XP190 N, XP 160, H180J, H190, Q165; Olympus Medical, Tokyo, Japan).

Statistical analysis {#sec2.4}
--------------------

Descriptive statistics were expressed as a median (range), and mean ± standard deviation (SD) for continuous variables and as frequencies (%) for categorical variables. Statistical comparisons between EoE patients from general population (EoE group) and children with EA and EoE (EA/EoE group) were analyzed using Mann Whitney Wilcoxon Test for continuous variables. Fisher exact test and χ2 test was used for nominal variables. A p-value of ≤0.05 was considered significant. Statistical analyses were performed using Prism version 6.0 (GraphPad Software, Inc., San Diego, CA, USA).

Results {#sec3}
=======

During the study period, clinical charts of 370 patients with EA and 118 patients with EoE were reviewed. Among these, 15 children with both EA and EoE (EA/EoE group) were identified; therefore, 4.0% of EA patients developed EoE and 12.7% of EoE children had a previous history of EA repair.

All 15 children of the EA/EoE group were in follow-up since birth. The median age at last visit was 9 years (range 4.8--18) and a male predominance (66.6%) was detected. The type C was the most dominant subtype of EA (86.6%). Six children (40.0%) had LGEA (all underwent esophago-esophageal anastomosis). Associated congenital defects were reported in 11 patients (73.3%). History of AS was observed in 12 (80%) patients, 5 of them (33.3%) had recurrent/refractory AS. Five (33.3%) children previously underwent antireflux procedures. Demographics and disease characteristics of EA/EoE children are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Demographics and EA characteristics in children with EA and EoE (EA/EoE group)Table 1Number of patients15Age at last visit \[years; median (range)\]9.0 (4.8--18)male/female10/5Type of EA[a](#tbl1fna){ref-type="table-fn"} \[number (percentage)\] Type A1 (6.6) Type B1 (6.6) Type C13 (86.6) Type D0 (0.0) Type E0 (0.0)Long gap EA[b](#tbl1fnb){ref-type="table-fn"} \[number (percentage)\]6 (40.0)Associated anomalies \[number (percentage)\]11 (73.3) VACTERL association4 (26.6) Heart defect4 (26.6) CNS abnormalities3 (20.0) Anorectal malformation2 (13.3) Pulmonary defect1 (6.6) Genitourinary defect1 (6.6)History of AS \[number (percentage)\]12 (80) Recurrent/refractory AS[c](#tbl1fnc){ref-type="table-fn"}5 (33.3)Previous antireflux surgery \[number (percentage)\]5 (33.3) Toupet fundoplication3 (20.0) Nissen fundoplication2 (13.3)[^1][^2][^3][^4]

Comparison of clinical characteristics between EA/EoE group and EoE patients from general population (EoE group) is illustrated in [Table 2](#tbl2){ref-type="table"}. Overall, among all 118 EoE children, male-to-female prevalence ratio was 2.5 with no difference between groups (2.0 *vs* 2.6 for EA/EoE and EoE group, respectively; p = 0.75). At the time of EoE diagnosis, EA/EoE children were significantly younger than EoE patients from general population (median: 4 *vs* 10.9 years; p \< 0.0001). Peak EOS/HPF did not differ between groups (mean ± standard deviation: 50.1 ± 26 *vs* 59.8 ± 29 EOS/HPF; p = 0.24). Overall, 66.1% of children had allergies with no difference between groups (53.3 *vs* 67.9%; p = 0.38). PPI-responder patients were significantly more prevalent in EA/EoE group that in EoE group (66.6% *vs* 35.9%; p = 0.045). Among the 5 EA/EoE patients who were non-PPI-responders, 2 achieved clinical and histological remission while on dietary treatment (milk free diet) and 3 on swallowed topical corticosteroid.Table 2Clinical characteristics of EA/EoE and EoE patientsTable 2EA/EoEEoEpNumber of patients15103Male/female (ratio)10/5 (2.0)75/28 (2.6)0.75[a](#tbl2fna){ref-type="table-fn"}Age at EoE diagnosis \[years; median (range)\]4 (1.1--12.5)10.9 (1.7--23.5)**\< 0.0001**[b](#tbl2fnb){ref-type="table-fn"}Peak EOS/HPF at diagnosis \[number; mean ± SD\]50.1 ± 2659.8 ± 290.24[b](#tbl2fnb){ref-type="table-fn"}History of allergy \[number (percentage)\]8 (53.3)70 (67.9%)0.38[a](#tbl2fna){ref-type="table-fn"}PPI-REE \[number (percentage)\]10 (66.6)37 (35.9)**0.045**[a](#tbl2fna){ref-type="table-fn"}[^5][^6][^7]

Discussion {#sec4}
==========

This retrospective series is the first from an Italian cohort to evaluate the coexistence of EA and EoE and confirms that EA patients are at high risk for developing EoE.

The prevalence of EoE in our cohort of EA survivors (4.0%) was much greater than the 0.1--0.57% estimated in general population,[@bib5] but lower than previously reported (9.5--30%).[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] Characteristics and main results of previous series are summarized in [Table 3](#tbl3){ref-type="table"}. Beside possible regional variability, the main factor accounting for this difference is the approach to esophageal biopsy sampling: "routine" versus "selective". Indeed, we collected biopsies only in symptomatic EA patients without AS and/or with typical endoscopic features of EoE,[@bib10] while other authors performed routine biopsies in all patients, even asymptomatic. It is still not clear whether all EA patients should undergo routine esophageal biopsies to rule out esophageal eosinophilia (EE). Current guidelines on EA recommend, with a low level of evidence, excluding EoE in symptomatic EA patients, especially before anti-reflux surgery.[@bib3]Table 3Details of studies reporting EoE prevalence in EA childrenTable 3Year of publicationStudy periodInstitution (Country)Total Nr of EA patientsEA/EoEEoE prevalenceStudy designPatients included*Dhaliwal* et al.[@bib11]20141999--2012SCH (Australia)1031817%retrospectiveAll surviving patients who had surgery for EA*Krishnan* et al.[@bib12]20182000--2014SCH (Australia)1102018%retrospective[\#](#tbl3fnhash){ref-type="table-fn"}*Petit* et al.[@bib13]20192005--2014CHU Sainte-Justine (Canada)731521%prospectiveChildren born with EA-TEF were prospectively included*Lardenois* et al.[@bib14]20192007--2015University Hospitals of Lille and Strasbourg (France)6369.5%prospectiveAll patients aged 15--20 years with medical history of EA*Yasuda* et al.[@bib15]20192016--2018Boston Children\'s Hospital (United States)3104715%[∗](#tbl3fnlowast){ref-type="table-fn"}retrospectivePatients with EA who underwent at least one upper endoscopy with biopsies*Pesce* et al.[@bib16]20192015--2017GOSH (United Kingdom) SCH (Australia)631930%retrospectiveAll children with EA referred consecutively either for refractory upper GI symptoms or as part of surveillance program[^8][^9][^10]

EE does not always mean EoE. Recent international consensus on EoE points out that the presence of EE on histologic examination without further consideration of the clinical presentation is not diagnostic of EoE. Authors also highlight that EoE is ultimately diagnosed after excluding other contributing factors for symptoms and EE.[@bib17] However, the application of the EoE clinical criteria to EA patients is problematic, since esophageal symptoms in EA patients might arise from many different underlying conditions.[@bib3]

Virtually all EA survivors have an impaired esophageal motility, which is the key pathophysiological factor leading to long-term digestive and respiratory morbidity.[@bib18]^,^[@bib19] It is conceivable that esophageal dysmotility in EA patients might play a pivotal causative role also in EoE development,[@bib20] increasing the risk of severe GERD and producing stasis of food and saliva into the esophageal lumen. Prolonged mucosal acid exposure time and retained material into the esophagus might cause itself mucosal injury and esophageal eosinophilic-predominant inflammation.[@bib21]^,^[@bib22] Moreover, esophageal stasis may also result in prolonged exposure to allergens (both aero and food allergens) which facilitates the inflammatory eosinophilic cascade in susceptible patients.[@bib20]

The topic of AS and its relation to EE and EoE deserves a specific point of discussion. AS is the most frequent post-operative complication of EA and must be first excluded in all symptomatic patients.[@bib3] AS may contribute to eosinophil inflammation due to stasis and retained bolus. Therefore, AS treatment by esophageal dilation may interrupt the chain of events leading to mucosal inflammation, by improving both anterograde and retrograde flow through the esophagus. A recently published case report describing the resolution of EE in a patient with achalasia, who underwent pneumatic dilation of the cardia, supports this speculation.[@bib23] On the other hand, patients with EA and EE were described to be at increased risk of recurrent/refractory AS formation,[@bib6] which remains a major challenge in the postoperative management of EA.[@bib10] Although the pathogenesis of recurrent/refractory AS is not fully understood, it is likely that the presence of EE, whether it be EoE or not, might play an important role in stricture formation.[@bib11] Treating EE with topical corticosteroids, by reversing the subepithelial fibrotic process, may possibly result in a reduction of AS recurrence, and subsequent need for further invasive procedures.[@bib6]

In the present study, we also aimed to compare demographic and disease characteristics between EA/EoE children and a large group of EoE patients from general population. Consistent with literature data on EoE,[@bib24] we found a strong male predominance and a high prevalence of atopic comorbidities (allergic rhinitis, asthma, food allergy), without significant differences between groups. Furthermore, no difference in tissue eosinophilia levels (peak EOS/HPF) was observed.

Similarities in gender distribution, atopic background and histopathological findings suggest that common genetic susceptibility factors might underlie EoE development in EA patients. This hypothesis is corroborated by the study of *Krishnan* et al. demonstrating a similar gene expression pattern between EoE patients with and without EA.[@bib12]

On the other hand, we observed a higher incidence and early onset of EoE in EA patients than in children from general population. Besides the above mentioned implication of the esophageal dysmotility, these findings might be related to other factors:[@bib6]^,^[@bib20] (1)- Early endoscopic surveillance in EA children might enable early diagnosis of EoE.; (2)- The majority (if not all) of EA children are exposed to early-life environment factors implicated in EoE pathogenesis such as admission to the neonatal intensive care unit, antibiotic and acid suppressant therapy in infancy, formula-only, or mixed feeding;[@bib25], [@bib26], [@bib27] (3) Genetic association between EA and EoE through mutations in the Forkhead box (FOX) gene has been hypothesized[@bib28]

Interestingly, we observed a significantly higher percentage of PPI-responders in EA/EoE patients than in the EoE group. Different mechanisms have been proposed to explain the PPI response in EoE.[@bib17], [@bib29] By restoring the acid reflux-induced impairment of mucosal integrity, PPIs correct the abnormal mucosal permeability and prevent antigen penetration.[@bib30] Gastric acid-inhibiting effect is likely to have a significant role in resolving EE in EA children because of their considerably higher risk of developing severe GERD with prolonged esophageal acid exposure time.[@bib3]^,^[@bib15]^,^[@bib16]^,^[@bib31] PPIs have been shown to also exert anti-inflammatory effects,[@bib17] by inhibiting the production of pro-inflammatory cytokines and adhesion molecules that act as ligands on the eosinophil cell surface.[@bib32], [@bib33], [@bib34] Of course, as for EoE from general population, these anti-inflammatory properties of PPIs can also explain PPI-REE observed in EA patients without evidence of GERD.

This study has some limitations to be considered. First, our findings may be somewhat limited by the retrospective nature. On the other hand, our study analyzed the largest cohort ever reported of patients with EA (370) and EoE (118). Our "selective" approach in performing esophageal biopsies likely underestimates the prevalence of EE in EA patients, compared to the "routine" approach of other studies. On the other hand, as pointed out by *Yasuda* et al., "eosinophil count alone in EA patients to diagnose EoE as previously reported is likely insufficient".[@bib15] Indeed, EA patients labeled as having EoE in previous "routine" studies might not meet the clinical criteria or may not have received evaluation to exclude other possible contributing causes for symptoms and EE, and therefore may overestimate the prevalence of EoE in EA. Perhaps our cohort more accurately reflects the risk compared to the considerably higher risks detailed in previous reports. In our view, the *"a posteriori"* analysis over a long period (13 years) of symptomatic EA children without AS, could represent the most reliable picture of the relationship between EA and "true" EoE.

In summary, our study confirms in our Italian cohort that EA patients are more prone to develop EoE than general population,[@bib3] but it notably estimates a lower risk than previously reported. Established risk factors for EoE, such as male gender and history of atopy, may contribute to EoE development in EA patients as with general population. Our study suggests that adapted criteria for EoE diagnosis should be developed for EA patients. Indeed, while underdiagnosis of EoE may occur if routine biopsies are not obtained in all patients with EA,[@bib3] overdiagnosis may also occur if eosinophilia is present, but symptoms of esophageal dysfunction relate to complications of EA rather than EoE. It should be kept in mind that EoE is a specific chronic condition carrying a significant burden of disease, as it requires intensive monitoring and long-term medications or dietary restrictions.[@bib35] Moreover, the high prevalence of PPI-REE in our EA/EoE population re-emphasizes the importance of a PPI-trial that has been recently removed from the diagnostic algorithm for EoE.[@bib17]

Growing evidence indicates that EoE is an umbrella term for conditions that are unified by EE, but that different disease subgroups with various inflammatory esophageal patterns and/or different clinical features exist.[@bib36] Our study supports the concept that EoE in EA represents a specific subtype of EoE and strongly sustains the vision toward tailored treatment strategies according to different EoE phenotypes.[@bib36] Future research should devote more attention to the role of EE, whether it be EoE or not, in EA children, especially in those experiencing recurrent/refractory AS.
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[^1]: **Abbreviation**: EA, esophageal atresia; EoE, eosinophilic esophagitis; VACTERL, Vertebra-Anorectal-Cardiac-Tracheoesophageal-Renal-Limb; CNS, central nervous system; AS, anastomotic stricture.

[^2]: According to the Gross classification[@bib7].

[^3]: ≥ 3 vertebral bodies between the proximal and distal esophageal segments[@bib8].

[^4]: According to the ESPGHAN and ESGE definition.[@bib9]

[^5]: **Abbreviation**: EA, esophageal atresia; EoE, eosinophilic esophagitis; EOS/HPF, eosinophils per high-power field; PPI-REE, proton pump inhibitor - responsive esophageal eosinophilia; SD, standard deviation.

[^6]: Fisher\'s exact test.

[^7]: Mann Whitney test; bold text indicates a statistically significant difference.

[^8]: Abbreviation: EA, esophageal atresia; EoE, eosinophilic esophagitis; GOSH, Great Ormond Street Hospital; SCH, Sydney Children\'s Hospital.

[^9]: Non clearly detailed, conceivably as the study by *Dhaliwal* et al. (similar study periods were analyzed).

[^10]: Patients who met histologic criteria of \>15 eosinophils/high powered field.
